Press Release

Travel Vaccine Market Projected to be Dominated by the Hepatitis A Segment Through 2027

Rising awareness towards transnational infections and increasing inclination towards leisure travelling are contributing to the growth of the global travel vaccine market.


According to TechSci report on, “
Travel Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027, the global travel vaccine market is anticipated to register lucrative growth with formidable CAGR over the forecast period of 2023-2027. The market growth can be attributed to the rising incidence of travel-related viruses like hepatitis, Japanese encephalitis, meningitis, and yellow fever, among others. Besides, growing global arrivals of foreign visitors due to surge in leisure and business travelling has led to high demand for travel vaccines across the globe. With the emergence of new viruses, pharmaceutical companies and research institutes are increasingly focusing on testing and developing fresh, improved, and effective vaccines, which is anticipated to boost the growth of the global travel vaccine market. The COVID-19 pandemic acted as a catalyst to boost the demand for vaccines since many countries asked for vaccination certificates from arriving travelers. Post-pandemic, people have become more aware of the new kinds of viruses that could compromise their health. Hence, increasing awareness among population regarding various kinds of infections, owing to increased initiatives by the government and health authorities is supporting the market growth.

 


Browse over XX market data Figures spread through 110 Pages and an in-depth TOC on 
"TRAVEL VACCINE MARKET"

 


The global travel vaccine market is segmented by composition, disease indication, travel type, and regional distribution. Based on the composition, the market is bifurcated into mono vaccines and combination vaccines. The combination vaccines segment is anticipated to register the highest growth in the global travel vaccine market during the forecast period. People are inclined more towards combination travel vaccines since they provide enhanced protection against several diseases in fewer shots. Besides, licensed combination travel vaccines are just as safe and effective as mono vaccines. Moreover, scientists are more focused on developing and testing new combination vaccines, which is anticipated to fuel the segment growth in the coming years.

 


By disease indication, the market is divided
into Hepatitis A, DPT, Yellow Fever, Typhoid, Hepatitis B, Measles and Mumps, Rabies, Meningococcal, Varicella, Japanese Encephalitis, and others. The Hepatitis A is expected to hold the largest share in the global travel vaccine market, owing to the rising cases of Hepatitis A infection across the world. Hepatitis A is a serious liver disease caused by unknowingly ingesting objects, foods, or drinks contaminated by small amounts of stool from an infected person or even coming in close and personal contact with an infected person. The risk of Hepatitis A increases for travellers that visit rural areas, trek in backcountry areas, or eat or drink in settings of poor sanitation. Many national governments and health agencies are also taking action to raise awareness regarding Hepatitis A, which is fuelling the demand for Hepatitis A vaccines among travellers.  

 


Based on travel type, the market is bifurcated into domestic and international. The international travel segment is likely to dominate the global travel vaccine market, owing to increasing interest of travelers to visit exotic destinations where they may be at risk for a myriad of diseases. Several countries ask for international certificate of vaccination (ICV) approved by the World Health Organization (also known as yellow card) as a proof of vaccination against certain diseases from arriving travelers.

 


A list of major market players of the global travel vaccine market
includes:

  • GlaxoSmithKline, plc.
  • Sanofi S.A.
  • Novartis International AG
  • Merck KGaA
  • Pfizer Inc.
  • AstraZeneca Plc.
  • Abbott Laboratories, Inc.
  • F. Hoffmann-La Roche AG
  • CSL Limited
  • Johnson & Johnson


DOWNLOAD FREE SAMPLE REPORT

Customers can also request for 10% free customization on this report.


Rapid globalization and increasing personal discretionary income of the population have led to an increasing demand for leisure and business travel. With the growth in travel and tourism, there has been significant rise in transnational infections. Hence, people are increasingly opting for travel vaccines to protect themselves against serious health disorders. Currently, North America is leading the global travel vaccine market due to advanced healthcare infrastructure and availability of advanced vaccines in the region. However, Asia-Pacific region is expected to register the fastest growth in the global travel vaccine market, owing to increasing health awareness regarding various kinds of infections and rising need for travelling. Many research institutes and pharmaceutical organizations are involved in the research and development of new vaccines that are safe, effective, and cause less side-effects, which is likely to fuel the market growth in the coming years.” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.

 

Travel vaccine Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Composition (Mono Vaccines v/s Combination Vaccines), By Disease Indication (Hepatitis A, DPT, Yellow Fever, Typhoid, Hepatitis B, Measles and Mumps, Rabies, Meningococcal, Varicella, Japanese Encephalitis, Others), By Travel Type (Domestic v/s International) and By Region has evaluated the future growth potential of global travel vaccine market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in travel vaccine market.


Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com

Relevant News